STOCKHOLM, May 7, 2021 /PRNewswire/ -- On
6th May 2021, the Annual General Meeting (AGM) was
held in Immunovia AB (publ), 556730-4299. Due to the extraordinary
situation following the COVID-19-pandemic, the AGM was carried out
through advance voting pursuant to temporary legislation. Below is
a summary of the resolutions made at the AGM.
Allocation of the company's available profits
The AGM resolved that the company's available profits, SEK 565,437,678, shall be brought forward and
that no dividend shall be made.Fees for the board and the
auditor
The AGM resolved that the chairman of the board shall receive
SEK 550,000 and each of the other
members of the board shall receive SEK
240,000. Remuneration for committee work will amount to
SEK 30,000 for members of the audit
and remuneration committees, and SEK
50,000 for the chairmen of the audit and remuneration
committees. Travel expenses will be reimbursed in accordance with
company policy. Lastly, the auditor's fees are to be paid as per
approved invoice.
Fees for the board and the auditor
The AGM resolved that the chairman of the board shall receive
SEK 550,000 and each of the other
members of the board shall receive SEK
240,000. Remuneration for committee work will amount to
SEK 30,000 for members of the audit
and remuneration committees, and SEK
50,000 for the chairmen of the audit and remuneration
committees. Travel expenses will be reimbursed in accordance with
company policy. Lastly, the auditor's fees are to be paid as per
approved invoice.
Election of board members, chairman of the board and
auditors
The AGM resolved (i) that the number of board members shall be
seven, with no deputy members, (ii) to re-elect board members Carl
Borrebaeck, Mimmi Ekberg, Peter
Høngaard Andersen, Hans Johansson,
Christofer Sjögren and Ann-Christine
Sundell, (iii) to elect Martin Møller as a new board member
and (iv) to re-elect Carl Borrebaeck as chairman of the board.
Mats Grahn had declined re-election.
Lastly, the AGM resolved to re-elect authorised public accountant
Mats-Åke Andersson, HLB Auditoriet AB, as auditor of the company,
with authorised public accountant Martin
Gustafsson, HLB Auditoriet AB as deputy auditor.
Remuneration report and guidelines for remuneration to
management
The AGM approved the board's remuneration report, as well as the
guidelines for remuneration to the company's management proposed by
the board (after recommendation from the remuneration
committee).
Authorization for the board to resolve on new issue of
shares
The AGM authorized the board to resolve on one or several occasions
before the next AGM, on an issue of shares. Such issue may entail a
deviation from the shareholders' preferential right to subscribe
for new shares and also entail that payment of the new shares may
be made in cash, by consideration in kind or by set-off. The issue
may result in an aggregate increase in the share capital
corresponding to the issue of a maximum of 20 % of the number of
shares as per the 2021 AGM.
Amendment of the company's articles of association
The AGM resolved to amend the articles of association by (i)
increasing the number of allowed shares and the allowed share
capital, and (ii) adding a new item 9 (and amending the numbering
of subsequent items) allowing the board of directors to collect
powers of attorney in accordance with chapter 7 section 4, second
paragraph of the Swedish Companies Act and to resolve that the
shareholders shall have the right to vote in advance. The AGM
further resolved that the possibility to appoint deputy board
members be removed, in line with the provisions of the Swedish
Corporate Governance Code, necessitating an adjustment to article
6. In addition, the AGM resolved on a number of minor linguistic
and editorial adjustments, as well as adjustments resulting from
changes in legislation, to articles 1, 8, 9 and 11.
Minutes from the AGM
Minutes from the AGM (in Swedish) will be published on the
company's website, https://immunovia.com/sv/bolagsstamma/, not
later than during week 19. A copy of the minutes (excluding the
voting list) will be sent to shareholders who request this and
provide their address.
Immunovia AB (publ)
Board of Directors
For questions, please contact:
Hans Liljenborg, CFO
E-mail: hans.liljenborg@immunovia.com
phone number: +46(0)70 792 05 29
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. The final
validation study was completed in Q1 2021. The accreditation
process for Immunovia Inc. in Marlborough, Massachusetts, USA is ongoing and commercial
testing will begin in Q2 after the accreditation. The European
launch plan will be communicated Q2 2021.
IMMray™ PanCan-d will be the first blood-based test for early
diagnosis of pancreatic cancer on the market, with a potential to
significantly improve patient survival and outcome. The test will
be exclusively provided by Immunovia Inc., Marlborough, Massachusetts, USA.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/annual-general-meeting---immunovia-ab,c3342333
The following files are available for download:
https://mb.cision.com/Main/13121/3342333/1414057.pdf
|
Press release
(PDF)
|